Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia

Whitney W. Brown, Harald Jüppner, Craig B. Langman, Heather Price, Emily G. Farrow, Kenneth E. White, Kenneth L. McCormick

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Context: Previous studies have suggested a regulatory relationship between serum phosphorus, vitamin D, and fibroblast growth factor 23 (FGF23), a hormone that promotes renal excretion of phosphate. Despite these associations, the identity of the primary regulator of serum FGF23 is unresolved. Jansen's metaphyseal chondrodysplasia is a rare autosomal dominant disorder associated with short-limbed dwarfism and other characteristic skeletal abnormalities. This condition is caused by mutations in the PTH/PTHrP receptor that result in ligand-independent cAMP accumulation, thus rendering the receptor constitutively active. These patients typically exhibit asymptomatic hypercalcemia and hypophosphatemia despite low or undetectable serum levels of PTH and PTHrP. Evidence Acquisition: A literature search revealed that serum FGF23 levels had not been studied in patients with Jansen's syndrome, a disorder in which the biochemical features present a unique opportunity to study the possible relationship between FGF23 and calcium-phosphorus-vitamin D metabolism. A case of Jansen's syndrome is presented in which serum FGF23 concentrations, along with serum phosphorus and 1,25(OH)2 vitamin D levels, were measured and compared with those of age-matched controls. Evidence Synthesis: Serum FGF23 concentrations in the patient with Jansen's syndrome were found to be markedly and persistently elevated, compared with values in healthy, age-matched controls, despite hypophosphatemia and normal 1,25(OH)2 vitamin D levels. Conclusion: Together, our findings indicate that serum FGF23 could be governed by factor(s) other than serum phosphorus, potentially by activation of the PTH/PTHrP receptor in bone.

Original languageEnglish (US)
Pages (from-to)17-20
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Hypophosphatemia
Phosphorus
Serum
Parathyroid Hormone Receptor Type 1
Ergocalciferols
Vitamin D
Parathyroid Hormone-Related Protein
Jansen type metaphyseal chondrodysplasia
fibroblast growth factor 23
Dwarfism
Metabolism
Hypercalcemia
Bone
Chemical activation
Phosphates
Hormones
Ligands
Calcium
Bone and Bones
Mutation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. / Brown, Whitney W.; Jüppner, Harald; Langman, Craig B.; Price, Heather; Farrow, Emily G.; White, Kenneth E.; McCormick, Kenneth L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 1, 01.2009, p. 17-20.

Research output: Contribution to journalArticle

Brown, Whitney W. ; Jüppner, Harald ; Langman, Craig B. ; Price, Heather ; Farrow, Emily G. ; White, Kenneth E. ; McCormick, Kenneth L. / Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 1. pp. 17-20.
@article{91ed2ec8af054f00ac5a0e42e6ff3bfc,
title = "Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia",
abstract = "Context: Previous studies have suggested a regulatory relationship between serum phosphorus, vitamin D, and fibroblast growth factor 23 (FGF23), a hormone that promotes renal excretion of phosphate. Despite these associations, the identity of the primary regulator of serum FGF23 is unresolved. Jansen's metaphyseal chondrodysplasia is a rare autosomal dominant disorder associated with short-limbed dwarfism and other characteristic skeletal abnormalities. This condition is caused by mutations in the PTH/PTHrP receptor that result in ligand-independent cAMP accumulation, thus rendering the receptor constitutively active. These patients typically exhibit asymptomatic hypercalcemia and hypophosphatemia despite low or undetectable serum levels of PTH and PTHrP. Evidence Acquisition: A literature search revealed that serum FGF23 levels had not been studied in patients with Jansen's syndrome, a disorder in which the biochemical features present a unique opportunity to study the possible relationship between FGF23 and calcium-phosphorus-vitamin D metabolism. A case of Jansen's syndrome is presented in which serum FGF23 concentrations, along with serum phosphorus and 1,25(OH)2 vitamin D levels, were measured and compared with those of age-matched controls. Evidence Synthesis: Serum FGF23 concentrations in the patient with Jansen's syndrome were found to be markedly and persistently elevated, compared with values in healthy, age-matched controls, despite hypophosphatemia and normal 1,25(OH)2 vitamin D levels. Conclusion: Together, our findings indicate that serum FGF23 could be governed by factor(s) other than serum phosphorus, potentially by activation of the PTH/PTHrP receptor in bone.",
author = "Brown, {Whitney W.} and Harald J{\"u}ppner and Langman, {Craig B.} and Heather Price and Farrow, {Emily G.} and White, {Kenneth E.} and McCormick, {Kenneth L.}",
year = "2009",
month = "1",
doi = "10.1210/jc.2008-0220",
language = "English (US)",
volume = "94",
pages = "17--20",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia

AU - Brown, Whitney W.

AU - Jüppner, Harald

AU - Langman, Craig B.

AU - Price, Heather

AU - Farrow, Emily G.

AU - White, Kenneth E.

AU - McCormick, Kenneth L.

PY - 2009/1

Y1 - 2009/1

N2 - Context: Previous studies have suggested a regulatory relationship between serum phosphorus, vitamin D, and fibroblast growth factor 23 (FGF23), a hormone that promotes renal excretion of phosphate. Despite these associations, the identity of the primary regulator of serum FGF23 is unresolved. Jansen's metaphyseal chondrodysplasia is a rare autosomal dominant disorder associated with short-limbed dwarfism and other characteristic skeletal abnormalities. This condition is caused by mutations in the PTH/PTHrP receptor that result in ligand-independent cAMP accumulation, thus rendering the receptor constitutively active. These patients typically exhibit asymptomatic hypercalcemia and hypophosphatemia despite low or undetectable serum levels of PTH and PTHrP. Evidence Acquisition: A literature search revealed that serum FGF23 levels had not been studied in patients with Jansen's syndrome, a disorder in which the biochemical features present a unique opportunity to study the possible relationship between FGF23 and calcium-phosphorus-vitamin D metabolism. A case of Jansen's syndrome is presented in which serum FGF23 concentrations, along with serum phosphorus and 1,25(OH)2 vitamin D levels, were measured and compared with those of age-matched controls. Evidence Synthesis: Serum FGF23 concentrations in the patient with Jansen's syndrome were found to be markedly and persistently elevated, compared with values in healthy, age-matched controls, despite hypophosphatemia and normal 1,25(OH)2 vitamin D levels. Conclusion: Together, our findings indicate that serum FGF23 could be governed by factor(s) other than serum phosphorus, potentially by activation of the PTH/PTHrP receptor in bone.

AB - Context: Previous studies have suggested a regulatory relationship between serum phosphorus, vitamin D, and fibroblast growth factor 23 (FGF23), a hormone that promotes renal excretion of phosphate. Despite these associations, the identity of the primary regulator of serum FGF23 is unresolved. Jansen's metaphyseal chondrodysplasia is a rare autosomal dominant disorder associated with short-limbed dwarfism and other characteristic skeletal abnormalities. This condition is caused by mutations in the PTH/PTHrP receptor that result in ligand-independent cAMP accumulation, thus rendering the receptor constitutively active. These patients typically exhibit asymptomatic hypercalcemia and hypophosphatemia despite low or undetectable serum levels of PTH and PTHrP. Evidence Acquisition: A literature search revealed that serum FGF23 levels had not been studied in patients with Jansen's syndrome, a disorder in which the biochemical features present a unique opportunity to study the possible relationship between FGF23 and calcium-phosphorus-vitamin D metabolism. A case of Jansen's syndrome is presented in which serum FGF23 concentrations, along with serum phosphorus and 1,25(OH)2 vitamin D levels, were measured and compared with those of age-matched controls. Evidence Synthesis: Serum FGF23 concentrations in the patient with Jansen's syndrome were found to be markedly and persistently elevated, compared with values in healthy, age-matched controls, despite hypophosphatemia and normal 1,25(OH)2 vitamin D levels. Conclusion: Together, our findings indicate that serum FGF23 could be governed by factor(s) other than serum phosphorus, potentially by activation of the PTH/PTHrP receptor in bone.

UR - http://www.scopus.com/inward/record.url?scp=58149394434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149394434&partnerID=8YFLogxK

U2 - 10.1210/jc.2008-0220

DO - 10.1210/jc.2008-0220

M3 - Article

C2 - 18854401

AN - SCOPUS:58149394434

VL - 94

SP - 17

EP - 20

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -